DexCom Inc. ($DXCM) Stock Forecast: Up 7.4% Today

What is DexCom Inc.?

DexCom (DXCM) is a company specializing in continuous glucose monitoring systems, with a focus on improving the lives of individuals with diabetes. The stock had a strong bullish movement today.

Why is DexCom Inc. going up?

DXCM stock is up 7.4% on Feb 13, 2026 20:36

• Despite DexCom's strong financial performance, including beating Q4 earnings and revenue estimates, the stock experienced a slight fall in after-hours trading. This could be due to profit-taking by investors after a recent surge in the stock price.
• The anticipation of expanded Medicare coverage for CGMs for Type 2 diabetes patients is a positive development for DexCom, indicating potential growth opportunities in a new market segment.
• The company's 2026 revenue forecast falling slightly below analysts' expectations may have contributed to some investor uncertainty, leading to the mixed market movement despite the positive earnings beat.
• Overall, the bullish movement in DexCom's stock today could be attributed to the company's strong financial performance, anticipation of expanded market opportunities, and positive analyst reactions, despite some lingering concerns about revenue forecasts.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth

DexCom (DXCM) reported strong fourth-quarter and full-year 2025 results, beating analyst estimates for both earnings and revenue, driven by robust G7 rollout and international expansion. Despite this positive financial performance and optimistic 2026 guidance, the company's stock experienced a slight fall in after-hours trading, and has seen a significant decline over the past six months. Key growth drivers include solid customer demand, expanding access for type 2 non-insulin users, and advancements in its G7 15 Day system and future product pipelines.

https://finviz.com/news/310920/dexcom-stock-falls-despite-q4-earnings-beat-g7-rollout-drives-growth

Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes

Dexcom is actively pursuing expanded Medicare coverage for its continuous glucose monitors (CGMs) for individuals with Type 2 diabetes who do not use insulin, with CEO Jake Leach anticipating a coverage proposal in the first half of 2026. The company is generating real-world data and has a randomized controlled trial planned to support this expansion, building on recent commercial coverage and updated American Diabetes Association guidelines. Dexcom also recently launched a 15-day G7 sensor, which has contributed to increased demand.

https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/

Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations

Dexcom reported strong 2025 revenues of $4.66bn, driven by demand for its continuous glucose monitoring systems, with Q4 2025 earnings at $1.26bn. Despite this, the company's 2026 revenue forecast of $5.16bn to $5.25bn, while showing double-digit growth, fell slightly below analysts' expectations. CEO Jake Leach outlined plans for 2026, including increasing awareness of the new G7 15-day device, enhancing customer experience, and expanding international market share, particularly with the Smart Basal launch.

https://finance.yahoo.com/news/dexcom-reports-2025-revenues-4-171045525.html

DexCom (NASDAQ:DXCM) Stock Price Up 8.4% on Earnings Beat

DexCom's stock price surged 8.4% after the company successfully beat Q4 earnings and revenue estimates. Analysts have reacted positively, with Mizuho and BTIG raising their price targets, contributing to a consensus target around $85.05. Despite an elevated valuation and past underperformance, the company's strong demand for continuous glucose monitors and an AI upgrade for its Stelo product suggest potential for continued growth.

https://www.marketbeat.com/instant-alerts/dexcom-nasdaqdxcm-stock-price-up-84-on-earnings-beat-2026-02-13/

DexCom, Inc. (NASDAQ:DXCM) Q4 2025 Earnings Call Transcript

DexCom, Inc. reported strong Q4 and full-year 2025 results, with revenue exceeding guidance and EPS beating expectations. The company highlighted the successful broad rollout of its DexCom G7 15-day system and the upcoming launch of DexCom Smart Basal. CEO Jacob Steven Leach emphasized continued innovation, improved customer experience, and significant international expansion opportunities, particularly anticipating broader access for type 2 non-insulin users in the US and globally.

https://www.insidermonkey.com/blog/dexcom-inc-nasdaqdxcm-q4-2025-earnings-call-transcript-1695372/

Trending Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.6% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 6.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 7.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 6.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.9% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 5.4% Today

Wingstop Inc. ($WING) Stock Forecast: Down 6.8% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.3% Today

DexCom Inc. Price History

03.01.2026 - DXCM Stock was down 1.8%

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

05.00.2026 - DXCM Stock was up 2.8%

• The bullish movement in DXCM stock today can be attributed to the company's position at an inflection point in the competitive glucose-monitoring market, with positive sentiment from analysts on its future prospects.
• Recent insider transactions, including some purchases at lower prices, suggest continued long-term confidence in DXCM despite short-term valuation concerns, contributing to the positive momentum.
• The company's innovative products and favorable regulatory environment are likely driving investor optimism and contributing to the stock's strong performance in today's trading session.

10.11.2025 - DXCM Stock was up 4.1%

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

11.10.2025 - DXCM Stock was up 5.1%

• Today's bullish movement in DXCM's stock may be linked to the favorable market response to its robust Q3 growth and expanded CGM coverage, positioning the company for ongoing adoption despite growing competition.
• Despite facing legal challenges such as securities fraud class action lawsuits and allegations of securities law violations, investors appear to be more focused on the company's growth potential and momentum driven by innovation.
• While some investors have taken a bearish stance in the options market, this sentiment does not seem to have significantly impacted DXCM's stock performance today, as the overall optimistic outlook on the company's future prospects overshadowed these issues.

12.00.2026 - DXCM Stock was up 5.1%

• Dexcom experienced a strong bullish movement recently due to several positive factors:
• The fourth-quarter revenue surpassed expectations, mainly due to the successful launch of the G7 15-Day sensor, showcasing the company's innovation and responsiveness to market needs.
• The appointment of a new President and CEO, Jake Leach, coupled with plans to introduce an AI-enabled Stelo app, reflects a strategic shift towards advanced technology in diabetes management.
• Analysts have expressed optimistic views on Dexcom's performance for 2026, projecting revenue growth and improved margins, which has boosted investor confidence and generated a bullish sentiment.
• Despite concerns raised by some analysts about weaker gross margins and potential pricing pressures, Dexcom's proactive approach to product development and leadership changes has outweighed these worries, leading to an increase in the stock price.

13.10.2025 - DXCM Stock was up 5.1%

• An upcoming lead plaintiff deadline in a securities lawsuit may have initially caused volatility in the stock.
• Despite bearish opinions in the options market, positive news surrounding DXCM's strong growth in Q3 and focus on innovation likely reassured investors and supported the bullish movement.
• Ongoing securities fraud class action lawsuits and legal reminders could have led to short-term fluctuations. However, the overall positive view on DXCM's performance and market position has been more prominent, driving the bullish trend.
• Investors appear to be placing more emphasis on the company's growth potential and competitive standing rather than its legal challenges, leading to an increase in the stock price.

06.00.2026 - DXCM Stock was up 5.1%

• The bullish movement in DXCM stock today can be attributed to the unveiling of a new app feature by a competitor aimed at enhancing mealtime decisions for individuals with diabetes. This innovation in the diabetes management space may have positively influenced investor sentiment towards DexCom.
• The market may also be reacting to the detailed overview of DexCom's stock performance and financial data, showcasing its fundamental strength and role in continuous glucose monitoring systems.
• Additionally, the nuanced view on Dexcom's valuation and long-term growth prospects from top institutional shareholders and recent insider trades might have instilled confidence in investors, contributing to the bullish momentum.

22.00.2026 - DXCM Stock was up 4.4%

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

13.01.2026 - DXCM Stock was up 8.3%

• DexCom's stock price saw an 8.4% increase following the company's surpassing of Q4 earnings and revenue expectations, demonstrating robust financial performance and market confidence.
• Analysts have revised upwards their price objectives for DXCM, with targets raised to $85.05 by Mizuho and $90.00 by BTIG, indicating positive sentiment and potential for further advancement.
• The successful launch of innovative products like the DexCom G7 15-day system and DexCom Smart Basal, alongside opportunities for expansion into international markets, have contributed to the positive market trend.
• Although encountering short-term challenges like trading below moving averages and a high P/E ratio, DexCom's strong financial position, optimistic market growth outlook, and upcoming catalysts point towards a bright future for the company.

13.01.2026 - DXCM Stock was up 7.4%

• Despite DexCom's strong financial performance, including beating Q4 earnings and revenue estimates, the stock experienced a slight fall in after-hours trading. This could be due to profit-taking by investors after a recent surge in the stock price.
• The anticipation of expanded Medicare coverage for CGMs for Type 2 diabetes patients is a positive development for DexCom, indicating potential growth opportunities in a new market segment.
• The company's 2026 revenue forecast falling slightly below analysts' expectations may have contributed to some investor uncertainty, leading to the mixed market movement despite the positive earnings beat.
• Overall, the bullish movement in DexCom's stock today could be attributed to the company's strong financial performance, anticipation of expanded market opportunities, and positive analyst reactions, despite some lingering concerns about revenue forecasts.

13.01.2026 - DXCM Stock was up 5.2%

• The positive movement in DXCM stock today is driven by the impressive Q4 performance and optimistic outlook shared during the earnings call.
• Mizuho's increase in price targets and "Buy" ratings maintained by Wells Fargo and Stifel reflect favorable analyst sentiment and confidence in the company's future growth potential.
• Despite some immediate challenges like trading below moving averages and a high P/E ratio, investor confidence remains high due to DXCM's innovative products like the DexCom G7 15-day system and DexCom Smart Basal, as well as substantial international expansion opportunities.
• Anticipated catalysts in 2026, such as potential Medicare coverage and new product launches, contribute to the positive market sentiment surrounding DXCM, positioning it as a top choice in the diabetes sector and potentially undervalued per InvestingPro's Fair Value assessment.